Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Cancer-related expenditures increase faster than any other area of health care: JAMA

From 1999 through 2006 the use of diagnostic imaging for Medicare patients with cancer increased, with use of positron emission tomography increasing the most significantly, according to a study in the April 28 issue of JAMA. Imaging costs for these patients also increased, outpacing the rate of increase in total costs among Medicare beneficiaries with cancer.

28 Apr 2010

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Usually when all else fails with a technical device, a "reset" button can be pressed, preventing a glitch from going any further. What if that could be done with threats to a person's health? Investigators from The Cancer Institute of New Jersey and the Environmental & Occupational Health Sciences Institute which is jointly administered by UMDNJ-Robert Wood Johnson Medical School and Rutgers, The State University of New Jersey, have discovered that a form of a dietary trace element known as selenium can help reset a cell's "biological clock" when it is disrupted by a chemical cancer-causing agent (carcinogen).

28 Apr 2010

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Generex Biotechnology Corporation today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex, for multiple cancer indications.

28 Apr 2010

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

Ipsen, a global biopharmaceutical group, and Invida Group, the leading healthcare commercialization solutions partner in the Asia Pacific region, announced today an agreement for the exclusive distribution and promotion by Invida of Ipsen's drugs Diphereline® 3.75mg & 11.25mg, Somatuline® Autogel® and Increlex® in selected countries in South-East Asia.

27 Apr 2010

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

EDAP TMS SA, the global leader in therapeutic ultrasound, today announced its strategy for the ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial. Following the FDA Gastroenterology and Urology Devices Panel in December 2009 and the Company's January 2010 meeting with the FDA concerning its recommendations for the trial protocol, the Company has thoroughly evaluated all options aiming at an IDE submission in a feasible timeframe and with acceptable economics.

26 Apr 2010

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

Cigarette smoking is a major cause of illness and death worldwide. But it is a complex behavior, and how much people smoke, how hard they find it to quit, and the impact of long-term smoking on health varies greatly among individuals. A substantial portion of this variability is genetic. Two years ago, deCODE discovered the first common, single-letter variation in the sequence of the human genome, on chromosome 15q25, associated with nicotine addiction and risk of lung cancer.

26 Apr 2010

Personal risk of developing prostate cancer increases when more direct relatives are affected

For a long time now doctors have known that prostate cancer "runs in the family". Men with family members who have been diagnosed with the disease have an elevated risk of developing cancer of the prostate. But exactly how high is an individual person's risk? For whom and at what age should an early detection screening urgently be recommended?

24 Apr 2010

PCFT helps in effectively targeting cytotoxic antifolates to tumors: Study

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented a poster at the American Association for Cancer Research's 101st Annual Meeting 2010 that details their novel study of molecules that use a tumor's acidic microenvironment to help them tailor chemotherapeutic agents to kill the tumor.

23 Apr 2010

Potential new early cancer detection method using engineered gold nanoparticles

University of Missouri School of Medicine scientists explain a potentially new early cancer detection and treatment method using nanoparticles created at MU in an article published in the Proceedings of the National Academy of Sciences. The article illustrates how engineered gold nanoparticles tied to a cancer-specific receptor could be targeted to tumor cells to treat prostate, breast or lung cancers in humans.

23 Apr 2010

Insufficient evidence on prostate cancer radiation treatment

Reuters: "There is not enough evidence to sort out the effect of various radiation treatments for prostate cancer patients, especially newer, so-called focused radiation, an advisory panel told the U.S. Medicare agency on Wednesday.

23 Apr 2010

Better diagnostics in prostate cancer needed

A flurry of confusing research about the benefits of PSA testing has left many men and their physicians reticent to use a test that may be life-saving, says a panel of prostate cancer experts. The experts who gathered on Capitol Hill in Washington on Tuesday agreed that PSA testing, while not cancer-specific, is one of the best available tools for early detection of a cancer that kills 27,000 American men each year.

23 Apr 2010

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

Castrate-refractory prostate cancer, which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for the treatment of CRPC are lacking, and a number of factors must be considered when deciding between second-line hormonal therapy and chemotherapy.

23 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Aragon Pharmaceuticals raises $22M through Series B financing

Aragon Pharmaceuticals Inc. today announced that it has secured $22 million in Series B financing.

23 Apr 2010

DiagnoCure's proprietary prostate cancer biomarker PCA3 presented at 2010 EAU meeting

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that its proprietary prostate cancer biomarker PCA3 was the topic of over 13 presentations at the 2010 European Association of Urology meeting, the world largest urology event, held in Barcelona, Spain, with 14,000 registrants.

22 Apr 2010

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Gen-Probe's PROGENSA® PCA3 assay can help predict the outcome of initial prostate biopsies in men suspected of having prostate cancer, according to a study of the molecular urine test presented in a scientific poster last week at the 25th annual European Association of Urology (EAU) Congress in Barcelona, Spain.

22 Apr 2010

ASTRO President speaks on radiation therapy for treatment of prostate cancer at MEDCAC meeting

ASTRO President Anthony Zietman, M.D., spoke before the Medicare Evidence Development and Coverage Advisory Committee meeting today on radiation therapy for treatment of localized prostate cancer. MEDCAC provides advice and recommendations to the Centers for Medicare and Medicaid Services for what is covered by Medicare and Medicaid, based on scientific evidence.

22 Apr 2010

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Interest in cancer prevention is increasing as scientists continue to learn new information and confirm what was already suspected.

22 Apr 2010

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported results from two studies on the development of ribonuclease-based immunotoxins at the American Association for Cancer Research conference.

22 Apr 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Cancer-related expenditures increase faster than any other area of health care: JAMA

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

Personal risk of developing prostate cancer increases when more direct relatives are affected

PCFT helps in effectively targeting cytotoxic antifolates to tumors: Study

Potential new early cancer detection method using engineered gold nanoparticles

Insufficient evidence on prostate cancer radiation treatment

Better diagnostics in prostate cancer needed

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Aragon Pharmaceuticals raises $22M through Series B financing

DiagnoCure's proprietary prostate cancer biomarker PCA3 presented at 2010 EAU meeting

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

ASTRO President speaks on radiation therapy for treatment of prostate cancer at MEDCAC meeting

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in